Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2024 07:52 ET | Source: Research and Markets

Global Vertigo Treatment Market Forecast to Reach $1.6 Billion by 2030, Driven by the Rise in Benign Paroxysmal Positional Vertigo Prevalence

Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Vertigo Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
March 28, 2024 11:41 ET | Source: Research and Markets

Global Parkinson Disease Market Projected to Reach $8.8 Billion by 2030, Driven by Advancements and Growing Demand for Effective Treatments

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
June 26, 2023 05:18 ET | Source: Research and Markets

Global $481 Million Motion Sickness Treatment Market, 2023-2029: Rising Demand Among Millennial Travelers for Distinctive & Exclusive Travel Experiences Driving the Market

Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The Global Motion Sickness Treatment Market, 2023-2029 report has been added to ResearchAndMarkets.com's offering.The Global Motion Sickness Treatment...
May 16, 2022 07:13 ET | Source: Research and Markets

Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others

Dublin, May 16, 2022 (GLOBE NEWSWIRE) -- The "Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report...
August 23, 2021 04:18 ET | Source: Research and Markets

2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology

Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
June 26, 2017 07:30 ET | Source: Dermira, Inc.

Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition

MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
June 06, 2017 07:30 ET | Source: Dermira, Inc.

Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations

MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
May 30, 2017 16:05 ET | Source: Dermira, Inc.

Dermira to Present at Jefferies 2017 Global Healthcare Conference

MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
May 16, 2017 16:01 ET | Source: Dermira, Inc.

Dermira Announces Closing of 3.00% Convertible Senior Notes Offering

MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
May 10, 2017 21:32 ET | Source: Dermira, Inc.

Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes

MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...

Next Page keyboard_arrow_right